Conclusions: In patients who progressed following an initial
response to the induction course of therapy, the disease control rate in
the ipilimumab arms was 65%-75% compared to 0% in the gp100 arm upon
re-induction. These findings may have implications for the use of
ipilimumab therapy in the long-term management of advanced melanoma.... (Ipilimumab is the drug Bobby is getting in the clinical trial)
response to the induction course of therapy, the disease control rate in
the ipilimumab arms was 65%-75% compared to 0% in the gp100 arm upon
re-induction. These findings may have implications for the use of
ipilimumab therapy in the long-term management of advanced melanoma.... (Ipilimumab is the drug Bobby is getting in the clinical trial)